TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04073394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Intervention
Description: Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Lifestyle Intervention
Description: Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
Study: NCT03191474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-POWr Intervention
Description: All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management.
Study: NCT02210182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Pentamidine
Description: Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
Study: NCT04100733

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert Bladder Cancer Monitor
Description: Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Flexible cystoscopy (WL/NBI) and urinary cytology
Description: Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
Study: NCT01594203

Intervention type: OTHER
Intervention: F18-FGD PET/CT
Study: NCT03505775

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 23Na magnetic resonance imaging
Description: Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
Study: NCT04443608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patiromer Powder for Oral Suspension [Veltassa]
Description: Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical, hormonal and metabolic phenotyping
Description: * Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers.
Study: NCT04443608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
Study: NCT02331420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Description: A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: * Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~* Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~* Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~* Programs for diet and lifestyle modification, including reduced overall energy and fat intake (\<30% total fat, \<10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~* low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids).
Study: NCT03585543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Crisis Alert V2
Description: Intervention consists of a mHealth app delivered via smartphone
Study: NCT00699127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Lecture of information regarding prematurity, NICU hospitalization, etc.
Study: NCT03212937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICE Chemotherapy
Description: IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle
Study: NCT01282788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caterpillar Cereal
Description: Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
Study: NCT00513539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stenting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliary stenting
Study: NCT03052621

Intervention type: PROCEDURE
Intervention: Omental transposition
Description: Harvesting the omentum to cover irradiated defects of breast cancer

Intervention type: PROCEDURE
Intervention: Omental transposition
Description: Harvesting the omentum to cover irradiated defects of breast cancer
Study: NCT00864981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Study: NCT01181479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15 (cycles 1-13)
Description: AG200-15 containing ethinyl estradiol and levonorgestrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lessina crossover to AG200-15
Description: Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
Study: NCT00146471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed
Study: NCT02872441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: One blood sample of 50 milliliter 24 hours after the inclusion
Study: NCT02978807

Intervention type: PROCEDURE
Intervention: Point of care and venous screening
Study: NCT00710645

Intervention type: DEVICE
Intervention: Lido Workset
Description: The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
Study: NCT03304288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Low-dose rituximab was used in combination with ATRA or as the monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low-dose rituximab was used in combination with ATRA or as the monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: ATRA was used in combination with low-dose rituximab
Study: NCT02061800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS CD34+ Reagent System
Description: The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonographic studies
Description: * Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.
Study: NCT02061800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ Reagent System
Description: The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ Reagent System
Description: The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
Study: NCT01049776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
Study: NCT01602731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Medication Dispensing Device
Description: All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
Study: NCT00863616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO - SmartVest
Description: SmartVest with vest administered for 20min at 11-13Hz
Study: NCT03304522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-150 for 6 weeks.
Study: NCT01859403

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Genomics
Description: A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients receive the same dietary recommendation regardless of their genetic information
Study: NCT01305499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat days 3, 10
Description: Given orally on days 3, 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5AC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5AC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat days 10,17
Description: Given orally on days 10, 17
Study: NCT03917121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet injector
Description: * The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle attached dental syringe
Description: * The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated.
Study: NCT00994617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan and hydrochlorothiazide
Description: Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide switched over with Losartan at 8 weeks
Description: Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
Study: NCT00680225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection and TTT - ICG based
Description: Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
Study: NCT00960271

Intervention type: PROCEDURE
Intervention: EBUS
Description: a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
Study: NCT04274322

Intervention type: OTHER
Intervention: Nutrition support
Description: Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement

Intervention type: OTHER
Intervention: Nutrition support
Description: Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
Study: NCT01629303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral nerve modulation
Description: After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral nerve modulation
Description: After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks
Study: NCT01287663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin impregnated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no Permethrin impregnated
Study: NCT02047006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Description: Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours.
Study: NCT03425903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cryotherapy sessions
Description: Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
Study: NCT03182439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fit Bit Blaze
Description: Fit Bit Blaze Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fit Bit Blaze
Description: Fit Bit Blaze Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fit Bit Blaze
Description: Fit Bit Blaze Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fit Bit Blaze
Description: Fit Bit Blaze Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Garmin Forerunner 235
Description: Garmin Forerunner 235 Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Garmin Forerunner 235
Description: Garmin Forerunner 235 Heart Rate Monitoring Device
Study: NCT02061800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Study: NCT03182439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Garmin Forerunner 235
Description: Garmin Forerunner 235 Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Garmin Forerunner 235
Description: Garmin Forerunner 235 Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tom Tom Spark Cardio
Description: Tom Tom Spark Cardio Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tom Tom Spark Cardio
Description: Tom Tom Spark Cardio Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tom Tom Spark Cardio
Description: Tom Tom Spark Cardio Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tom Tom Spark Cardio
Description: Tom Tom Spark Cardio Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch
Description: Apple Watch Heart Rate Monitoring Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch
Description: Apple Watch Heart Rate Monitoring Device
Study: NCT02061800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Study: NCT03182439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch
Description: Apple Watch Heart Rate Monitoring Device